The licensing deal marks a diversification of Roche’s obesity pipeline as it seeks entry into the lucrative market.
Analysts are heralding functional cures in chronic hepatitis B as the next frontier in treatment for patients.
Takeda is preparing to launch Orzeyful in Japan, aiming to make it available to patients as soon as possible.
The update follows the detection of asymptomatic findings in the spine MRIs of five participants enrolled in the CAMPSIITE study.
Asedebart is a humanised anti-ACTH monoclonal antibody that blocks ACTH binding to melanocortin 2.
The CKD market is poised to grow at a CAGR of 9.8% from $4.3bn in 2025 to $10.9bn in 2035 across the 7MM.
